Skip to main content
. Author manuscript; available in PMC: 2018 Jul 10.
Published in final edited form as: Leukemia. 2017 Nov 29;32(4):1016–1022. doi: 10.1038/leu.2017.338

Figure 3. R763 cooperates with PKC412 and with dasatinib in producing growth inhibition in neoplastic mast cells (MC).

Figure 3

A: HMC-1.1 and HMC-1.2 cells (upper panel) were incubated with various concentrations of R763, PKC412, or a combination of both drugs a fixed ratio of drug concentrations for 48 hours. Lower panel: HMC-1.1 and HMC-1.2 cells were incubated in various concentrations of R763, dasatinib, or a combination of both drugs at a fixed ratio of drug concentrations for 48 hours. Results are expressed as percent of control and represent the mean±S.D. of triplicates. B: ROSA KIT WT and ROSAKIT D816V cells (upper panel) were incubated with various concentrations of R763, PKC412, or a combination of both drugs at a fixed ratio of drug concentrations for 48 hours. Lower panel: ROSA KIT WT and ROSAKIT D816V cells were incubated with various concentrations of R763, dasatinib, or a combination of both drugs at a fixed ratio of drug concetrations for 48 hours. Results are expressed as percent of control and represent the mean±S.D. of triplicates.